Revisiting the Role of Antiarrhythmic Drugs in Prevention of Atrial Fibrillation Recurrence: A Single Center Retrospective Review

Overview

Journal Cardiol Res

Specialty Cardiology & Vascular Diseases

Date 2018 Jun 16

PMID 29904452

Citations 2

Authors

Daniel An Mascarenhas

Munish Sharma

Affiliations

Soon will be listed here.

Abstract

Background: We conducted a retrospective analysis to revisit the efficacy of four different commonly used antiarrhythmic drugs (AADs) in a single community hospital setting in the U.S. We used cardiac implantable electronic devices (CIEDs) to continuously monitor the patients for maintenance of sinus rhythm. The CIEDs in our study included insertable cardiac monitor (ICM), permanent pacemaker (PPM) and cardiac resynchronization therapy-defibrillator (CRT-D). The aim was to compare efficacy of commonly used AADs for maintenance of sinus rhythm in atrial fibrillation (AF) patients.

Methods: We conducted our retrospective study in a real world practice setting. We analyzed electronic medical records of 145 consecutive patients with paroxysmal and persistent AF who were treated with AADs for maintenance of sinus rhythm between the period of April 2014 and February 2018.

Results: Total 34 out of 145 patients (23.45%) had AF recurrence. The mean duration of first AF recurrence in total patient cohort was 18.01 ± 12 months. There was no major difference in efficacy in terms of prevention of first episode of AF recurrence among commonly used class III and class IC AADs.

Conclusions: Higher doses clearly seem to be more effective in preventing the recurrence of AF in class III AADs; sotalol and amiodarone. Use of CIEDs helps to continuously monitor patients for recurrence of AF and detects proarrhythmic effects of AADs.

Citing Articles

Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis.

Singh J, Blomstrom-Lundqvist C, Turakhia M, Camm A, Fazeli M, Kreidieh B Clin Cardiol. 2023; 46(6):589-597.

PMID: 37025083 PMC: 10270269. DOI: 10.1002/clc.24011.

Outpatient Initiation of Sotalol in Patients with Atrial Fibrillation: Utility of Cardiac Implantable Electronic Devices for Therapy Monitoring.

Mascarenhas D, Mudumbi P, Kantharia B Am J Cardiovasc Drugs. 2021; 21(6):693-700.

PMID: 34291437 PMC: 8295005. DOI: 10.1007/s40256-021-00493-7.

References

Singh B, Singh S, Reda D, Tang X, Lopez B, Harris C . Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352(18):1861-72. DOI: 10.1056/NEJMoa041705. View

Van Gelder I, Hagens V, Bosker H, Kingma J, Kamp O, Kingma T . A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347(23):1834-40. DOI: 10.1056/NEJMoa021375. View

Pritchett E . Management of atrial fibrillation. N Engl J Med. 1992; 326(19):1264-71. DOI: 10.1056/NEJM199205073261906. View

McNamara R, Tamariz L, Segal J, Bass E . Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003; 139(12):1018-33. DOI: 10.7326/0003-4819-139-12-200312160-00012. View

January C, Estes 3rd N, Page R, Ezekowitz M, Slotwiner D, Jackman W . 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010; 57(2):223-42. DOI: 10.1016/j.jacc.2010.10.001. View

Lip G, Brechin C, Lane D . The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012; 142(6):1489-1498. DOI: 10.1378/chest.11-2888. View

Roy D, Talajic M, Dorian P, Connolly S, Eisenberg M, Green M . Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000; 342(13):913-20. DOI: 10.1056/NEJM200003303421302. View

Flaker G, Blackshear J, McBride R, Kronmal R, Halperin J, Hart R . Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992; 20(3):527-32. DOI: 10.1016/0735-1097(92)90003-6. View

Lafuente-Lafuente C, Longas-Tejero M, Bergmann J, Belmin J . Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012; (5):CD005049. DOI: 10.1002/14651858.CD005049.pub3. View

10.

Coplen S, Antman E, Berlin J, Hewitt P, CHALMERS T . Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990; 82(4):1106-16. DOI: 10.1161/01.cir.82.4.1106. View

11.

Wyse D, Waldo A, DiMarco J, Domanski M, Rosenberg Y, Schron E . A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347(23):1825-33. DOI: 10.1056/NEJMoa021328. View

12.

January C, Samuel Wann L, Alpert J, Calkins H, Cigarroa J, Cleveland Jr J . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23):2071-104. DOI: 10.1161/CIR.0000000000000040. View

13.

Naccarelli G, Varker H, Lin J, Schulman K . Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009; 104(11):1534-9. DOI: 10.1016/j.amjcard.2009.07.022. View

14.

Mascarenhas D, Farooq M, Ziegler P, Kantharia B . Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding. Europace. 2015; 18(6):799-806. DOI: 10.1093/europace/euv350. View

15.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893-2962. DOI: 10.1093/eurheartj/ehw210. View

16.

MORRIS Jr J, ENTMAN M, NORTH W, Kong Y, McIntosh H . THE CHANGES IN CARDIAC OUTPUT WITH REVERSION OF ATRIAL FIBRILLATION TO SINUS RHYTHM. Circulation. 1965; 31:670-8. DOI: 10.1161/01.cir.31.5.670. View

17.

Snow V, Weiss K, Lefevre M, McNamara R, Bass E, Green L . Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2003; 139(12):1009-17. DOI: 10.7326/0003-4819-139-12-200312160-00011. View

18.

Lafuente-Lafuente C, Mouly S, Longas-Tejero M, Mahe I, Bergmann J . Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006; 166(7):719-28. DOI: 10.1001/archinte.166.7.719. View

19.

. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154(13):1449-57. View